News
Join WFH for Virtual World Hemophilia Day on April 14. See How Your Community Can Get Involved!
COVID-19
Tuesday April 14th 1 – 1:30pm (EDT) – Learn how your community can safely GET+INVOLVED. Join us for a brief overview of…
Bleeding Disorders and Covid-19 Webinar, April 9: Facts and Risks for People with Bleeding Disorders
COVID-19
On Thursday, April 9th, at 10:00 am EST, the World Federation of Hemophilia (WFH) will host a 60-minute webinar for the bleeding…
Supplemental MASAC Statement Regarding Home Delivery and Refill Under State of Emergency Declaration
COVID-19
Patients on home therapy receive regular shipments of clotting factor concentrate (CFC) or non-factor replacement therapy (e.g., emicizumab-kxwh) from their pharmacy providers,…
Industry Forms Alliance to Develop Potential Treatment for Patients with Serious COVID-19 Complications
COVID-19
An international group of pharmaceutical companies have joined an alliance, with the purpose of pooling their industry technologies and expertise to develop…
Specific Risks of COVID-19 to the Bleeding Disorders Community
COVID-19
WFH COVID-19 Task Force: Assad Haffar, Cedric Hermans, Barbara Konkle, Brian O’Mahony, David Page, Flora Peyvandi, Steve Pipe, Mark Skinner and Radek…
The FDA Releases a New Webpage During Covid-19 Outbreak
COVID-19
The U.S. Food and Drug Administration (FDA) released a new webpage of information to help address questions patients and caregivers may have…
HTC Visits and COVID-19
COVID-19
The National Hemophilia Foundation is monitoring the availability of access to hemophilia treatment centers (HTCs) during the COVID-19 pandemic. Our HTC network…
GLHF Advocated for the Bleeding Disorders Community in Washington, D.C.
GLHF News
At the end of February, to kick off March as Bleeding Disorders Awareness Month, GLHF joined more than 400 members of the…
Wisconsin Legislative Day Offered Stories, Experiences and Strength with Lawmakers
GLHF News
On March 4, GLHF headed to Madison for our annual Wisconsin Legislative Day – a chance to share with lawmakers the true…
Supplemental MASAC Statement Regarding Home Delivery and Refill Under State of Emergency Declaration
COVID-19
Patients on home therapy receive regular shipments of clotting factor concentrate (CFC) or non-factor replacement therapy (e.g., emicizumab-kxwh) from their pharmacy providers,…
Town Hall Webinar – Insurance: Coping During COVID-19
COVID-19
On March 27th, experts from NHF answered your questions regarding changes in insurance in our townhall webinar: Insurance: Coping During COVID-19. …
MASAC Issues Four New Documents
Industry News & Research
The National Hemophilia Foundation’s (NHF’s) Medical and Scientific Advisory Council (MASAC) issued four new documents, which were adopted by NHF’s Board of…
Milwaukee’s Best Bloody Brings Together Bars, Clients and Greater Milwaukee to Support the Bleeding Disorders Community
GLHF News
DRINK LOCAL. GIVE LOCAL. When GLHF started Milwaukee’s Best Bloody eight years ago, we were looking for a fresh way to raise…
Dr. Valentino’s COVID-19 Town Hall Webinar
COVID-19
On March 20th, NHF’s President and CEO answered your questions about how COVID-19 affects our community. You can watch the webinar in…
GLHF Letter to the Community on COVID-19
COVID-19, GLHF News
Dear GLHF Community Members, We are thinking of you every day. As we navigate this current health crisis together, our primary concern is,…
Health and Wellness Update from NHF’s Dr. Leonard Valentino
COVID-19
I know many of you are overwhelmed with often-conflicting information on the COVID-19 virus. As a doctor and researcher, the health of…
Coverage Concerns and Unanswered Questions: We Get It
COVID-19
As a community, we know how important it is for people with bleeding disorders to maintain comprehensive health insurance. Amid the uncertainty…
Three Concizumab Trials Halted by Novo Nordisk
Industry News & Research
Novo Nordisk recently announced that they have “paused” three clinical trials for their investigational subcutaneous therapy concizumab. The therapy is developed using…
Updates on Product Availability During COVID-19 Outbreak
COVID-19
NHF will be posting all communications from pharmaceutical companies regarding any potential affects that the COVID-19 pandemic could have on the manufacture…
Statement from Len Valentino on COVID-19
COVID-19
As we continue to monitor the COVID-19 outbreak in the US and around the world, we understand the uncertainty that it may…
Takeda Responds to HFA-NHF Letter on VONVENDI Recall
Industry News & Research
As previously reported by HFA and NHF, Takeda announced the recall of two lots of VONVENDI von Willebrand factor (recombinant) 1,300 I.U….
NHF Letter to the Community on COVID-19
COVID-19
The greatest asset at NHF is the community we serve – our family of staff and volunteers. We are aware of the…
MASAC Letter to the Community Regarding the Coronavirus Disease 2019
COVID-19
The Centers for Disease Control and Prevention (CDC) is responding to the rapidly evolving situation of the outbreak of respiratory disease (COVID-19)…
Medexus Acquires XINITY® from Aptevo
Industry News & Research
Aptevo Theraoeutics has sold their recombinant factor IX product IXINITY® to Canada-based Medexus Pharmaceuticals. IXINITY®, which first received approval from the U.S….